NewAmsterdam Pharma Company (NAMS) announced the appointments of Mark McKenna and Wouter Joustra to its Board of Directors. McKenna and Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024. McKenna currently serves as Chairman of the board of directors of Apogee Therapeutics ( APGE). Joustra is a General Partner at Forbion, a leading global life sciences venture capital firm with deep expertise in Europe.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma completes enrollment for Phase 3 TANDEM trial
- NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- NewAmsterdam Pharma Secures Key Patent, Eyes Commercialization
- NewAmsterdam Pharma announces USPTO issued patent for Obicetrapib